tiprankstipranks
Trending News
More News >
TipRanksTop Financial ExpertsInsidersVersant Venture Capital VI, L.P.

Versant Venture Capital VI, L.P. Insider Profile

4 Followers
Versant Venture Capital VI, L.P., Ten Percent Owner at Akero Therapeutics, holds 3.66M shares in LENZ Therapeutics (Ticker: LENZ), holds 5.65M shares in Monte Rosa Therapeutics (Ticker: GLUE), holds 6.21M shares in Black Diamond Therapeutics (Ticker: BDTX). Most recently, Versant Venture Capital VI, L.P. Sold ― shares of LENZ Therapeutics on Jul 01, 2025 for an estimated value of 6.09M.
tipranks
Versant Venture Capital VI, L.P.

Versant Venture Capital VI, L.P.
Akero Therapeutics (AKRO)
Ten Percent Owner

Ranked #27,448 out of 102,387 Corporate Insiders

Profitable Transactions

53%
8 out of 15 Profitable Transactions

Average Return

+3.00%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$372M
44.42%
28.85%
6.86%
6.42%
13.45% Others
A breakdown of Versant Venture Capital VI, L.P.'s holdings

Insider Roles

Akero Therapeutics
(AKRO)
Ten Percent Owner
LENZ Therapeutics
(LENZ)
Ten Percent Owner
Monte Rosa Therapeutics
(GLUE)
Ten Percent Owner
Tempest Therapeutics
(TPST)
Ten Percent Owner
+5 other positions
Roles that Versant Venture Capital VI, L.P. holds in companies

Most Profitable Insider Trade

Stock:
Black Diamond Therapeutics
(BDTX)
Rating:Informative Sell
Date:Aug 30, 2024 - Today
Return:+61.40%
The most profitable trade made by Versant Venture Capital VI, L.P.

Versant Venture Capital VI, L.P.'s Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Akero Therapeutics
Jan 21, 2020
Ten Percent Owner
Uninformative Sell
1.24M
$165.03M
OYST
Oyster Point Pharma
Jan 04, 2023
Uninformative Sell
$0.00
Black Diamond Therapeutics
Aug 30, 2024
Ten Percent Owner
Informative Sell
1.40M
$15.39M
Passage Bio
Mar 03, 2020
Ten Percent Owner
Uninformative Buy
$1.98M
PAND
Pandion Therapeutics
Jul 21, 2020
Uninformative Buy
$225.43M
Aligos Therapeutics
Oct 20, 2020
Ten Percent Owner
Uninformative Buy
$23.74M
Century Therapeutics
Aug 11, 2022
Ten Percent Owner
Uninformative Sell
7.17M
$6.79M
LENZ Therapeutics
Jul 01, 2025
Ten Percent Owner
Informative Sell
6.09M
$107.20M
Monte Rosa Therapeutics
Oct 30, 2024
Ten Percent Owner
Uninformative Buy
$25.49M
Tempest Therapeutics
Aug 12, 2024
Ten Percent Owner
Informative Sell
966.80K
$23.85M
Contineum Therapeutics, Inc. Class A
Ten Percent Owner
$2.08M
List of latest transactions for each holding click on a transaction to see Versant Venture Capital VI, L.P.'s performance on stock

Versant Venture Capital VI, L.P. insider profile FAQ

What is the percentage of profitable transactions made by Versant Venture Capital VI, L.P.?
The percentage of profitable transactions made by Versant Venture Capital VI, L.P. is 53%.
    What is the average return per transaction made by Versant Venture Capital VI, L.P.?
    The average return per transaction made by Versant Venture Capital VI, L.P. is 3.00%.
      What stocks does Versant Venture Capital VI, L.P. hold?
      Versant Venture Capital VI, L.P. holds: AKRO, OYST, BDTX, PASG, PAND, ALGS, IPSC, LENZ, GLUE, TPST, CTNM stocks.
        What was Versant Venture Capital VI, L.P.’s latest transaction?
        Versant Venture Capital VI, L.P. latest transaction was an Informative Sell of $6.09M.
          What was Versant Venture Capital VI, L.P.'s most profitable transaction?
          Versant Venture Capital VI, L.P.’s most profitable transaction was an Informative Sell of BDTX stock on August 30, 2024. The return on the trade was 61.40%.
            What is Versant Venture Capital VI, L.P.'s role in Akero Therapeutics?
            Versant Venture Capital VI, L.P.'s role in Akero Therapeutics is Ten Percent Owner.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.